A new era in Alzheimer’s disease management: exploring aducanumab’s potential

Boyu Jiang

doi:10.1117/12.3012915

8 January 2024 A new era in Alzheimer’s disease management: exploring aducanumab’s potential

Boyu Jiang

Proceedings Volume 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023); 129242S (2024) https://doi.org/10.1117/12.3012915
Event: 3rd International Conference on Biological Engineering and Medical Science (ICBioMed2023), 2023, ONLINE, United Kingdom

Abstract

Alzheimer’s disease (AD) is a deadly neurological condition associated with symptoms of memory loss and progressive cognitive deterioration. As an age-related disorder, it has been challenging the medical departments globally, leading to profound social and economic implications. Although its pathogenesis is not fully understood, many scientists have reached a consensus on the relationship between amyloid-beta protein peptide accumulation and cognitive decline. Aducanumab, an innovative monoclonal antibody treatment, targets the aggregated plaques and seeks to promote clearance to delay disease progression. Unlike conventional medications, aducanumab is the first therapy that allows for direct binding with amyloidogenic agents and, theoretically, leads to the activation of the immune system. In this review, the author provides an overview of Aducanumab’s mechanism and potential disadvantages, highlighting its critical role in slowing disease progression and emphasizing the controversy surrounding the accelerated approval. This paper also introduces investigational therapies that offer promising avenues offering hope for improved AD treatments and better quality of life for those affected. By revealing Aducanumab’s journey from research laboratories to the clinic, the global medical community can better understand the pathophysiology of AD, which further pave the way for a more comprehensive approach to managing this devastating neurological condition in the future.

Citation Download Citation

Boyu Jiang "A new era in Alzheimer’s disease management: exploring aducanumab’s potential", Proc. SPIE 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023), 129242S (8 January 2024); https://doi.org/10.1117/12.3012915

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
7 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Brain

Alzheimer disease

Proteins

Alzheimer's disease

Clinical trials

Monoclonal antibodies

Neurological disorders

Show All Keywords

Keywords/Phrases

Search In:

Publication Years